

Author's Accepted Manuscript



A 17-gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined mpMRI fusion-targeted and systematic prostate biopsy

Amirali Salmasi , Jonathan Said , Alan W. Shindel , Pooria Khoshnoodi , Ely R. Felker , Anthony E. Sisk , Jr., Tristan Grogan , Debbie McCullough , John Bennett , Helen Bailey , H. Jeffrey Lawrence , David A. Elashoff , Leonard S. Marks , Steven S. Raman , Phillip G. Febbo , Robert E. Reiter

PII: S0022-5347(18)42488-3
DOI: [10.1016/j.juro.2018.03.004](https://doi.org/10.1016/j.juro.2018.03.004)
Reference: JURO 15478

To appear in: *The Journal of Urology*
Accepted Date: 1 March 2018

Please cite this article as: Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE Jr., Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, Reiter RE, A 17-gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined mpMRI fusion-targeted and systematic prostate biopsy, *The Journal of Urology*® (2018), doi: 10.1016/j.juro.2018.03.004.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

Embargo Policy

All article content is under embargo until uncorrected proof of the article becomes available online.

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to jumedia@elsevier.com.

A 17-gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined mpMRI fusion-targeted and systematic prostate biopsy

Amirali Salmasi¹, Jonathan Said², Alan W. Shindel³, Pooria Khoshnoodi⁴, Ely R. Felker⁴, Anthony E. Sisk, Jr.², Tristan Grogan⁵, Debbie McCullough³, John Bennett³, Helen Bailey³, H. Jeffrey Lawrence³, David A. Elashoff⁵, Leonard S. Marks¹, Steven S. Raman^{1,4}, Phillip G. Febbo³, Robert E. Reiter^{1,6,*}

¹Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

²Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

³Genomic Health Inc, Redwood City, CA

⁴Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA

⁵Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, California, United States of America

⁶Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles,

*Corresponding author:

Robert E. Reiter, MD. MBA

Institute of Urologic Oncology

Wasserman Building, Third floor

300 Stein Plaza

Los Angeles, CA 90095

Email: RReiter@mednet.ucla.edu

Amirali Salmasi: asalmasi@mednet.ucla.edu

Jonathan Said: jsaid@mednet.ucla.edu

Alan W. Shindel: alan.shindel@ucsf.edu

Download English Version:

<https://daneshyari.com/en/article/8770412>

Download Persian Version:

<https://daneshyari.com/article/8770412>

[Daneshyari.com](https://daneshyari.com)